Your session is about to expire
← Back to Search
A for Ocular Hypertension
N/A
Waitlist Available
Led By Vladimir S Yakopson, MD
Research Sponsored by Walter Reed Army Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights
Study Summary
The purpose of the study is to compare the safety and efficacy of two drops used to lower eye pressure when given prior to a glaucoma laser procedure.
Eligible Conditions
- Ocular Hypertension
- Glaucoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 month
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Postoperative IOP
Secondary outcome measures
Overall IOP reduction post SLT
Trial Design
2Treatment groups
Active Control
Group I: AActive Control1 Intervention
Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT
Group II: IActive Control1 Intervention
Eyes receiving Apraclonidine 0.5% (Iopidine) prior to SLT
Find a Location
Who is running the clinical trial?
Walter Reed Army Medical CenterLead Sponsor
69 Previous Clinical Trials
20,896 Total Patients Enrolled
Vladimir S Yakopson, MDPrincipal InvestigatorWalter Reed AMC
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger